Stock DNA
Pharmaceuticals & Biotechnology
JPY 53,401 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-3.25
-476.81%
42.55
Total Returns (Price + Dividend) 
Healios KK for the last several years.
Risk Adjusted Returns v/s 
News

Healios KK Hits Day High with 8.47% Surge Amid Market Gains
Healios KK, a small-cap pharmaceutical company, saw its stock rise significantly on November 13, 2025, despite facing recent declines over the past week and month. However, the company has shown strong annual growth, outperforming the Japan Nikkei 225, while struggling with negative returns on equity and a high debt-to-equity ratio.
Read More
Healios KK Stock Hits Day Low of JPY 416 Amid Price Pressure
Healios KK, a small-cap pharmaceutical company, faced a notable stock decline today, reflecting ongoing challenges. Despite a strong year-to-date performance, the company has struggled with significant decreases in net sales and negative return on equity, raising concerns about its financial stability and long-term growth potential.
Read More
Healios KK Hits Day Low of JPY 457 Amid Price Pressure
Healios KK, a small-cap pharmaceutical company, faced significant stock volatility on October 14, 2025, with an 8.24% decline. Despite a strong year-to-date performance of 164.41%, the company struggles with negative return on equity and declining net sales, raising concerns about its long-term growth potential.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is -42.11% vs 111.11% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 16.24% vs -1,133.06% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 362.81% vs 34.44% in Dec 2023
YoY Growth in year ended Dec 2024 is -10.86% vs 26.25% in Dec 2023






